Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive brexpiprazole for depression with sleep-wake and circadian disturbance
ACTRN12619001456145Phase 4Terminated
- Sponsor
- University of Sydney
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brexpiprazole in major depressive disorder (MDD), sponsored by University of Sydney. Primary endpoints: QIDS-CR total score minus sleep items, Actigraphy sleep onset time and 1 more. Started Nov 2023; status: terminated.
02
Drugs
brexpiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12619001456145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001456145.